Patents by Inventor Muhammed Majeed

Muhammed Majeed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protective Effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC Against Drugs that Cause Channelopathies
    Publication number: 20190167585
    Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
    Type: Application
    Filed: January 11, 2019
    Publication date: June 6, 2019
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed
  • Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
    Patent number: 10293008
    Abstract: Disclosed herein is (i) a method related to the growth promotional activity of plant based fibers on Bacillus coagulans MTCC 5856; (ii) the combination of plant based fibers and Bacillus coagulans MTCC 5856 to inhibit Gram Negative pathogenic bacteria; and (iii) the production of short chain fatty acids (SCFA) by Bacillus coagulans MTCC 5856 using plant based fibers.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 21, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • PCR primers and methods thereof for the identification of bacillus coagulans
    Patent number: 10260112
    Abstract: The present invention discloses novel oligonucleotide primer sequences BC1, BC2 and BC3 for the identification of Bacillus coagulans. The invention also discloses a PCR based method for the identification of Bacillus coagulants using the aforesaid primers, wherein positive amplification with primer sets BC1, BC2 and negative amplification with primer set BC3 confirms the presence of Bacillus coagulans.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 16, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • Functional nutritional blend for thermo-metabolic performance
    Patent number: 10258073
    Abstract: The present invention discloses a functional nutritional blend comprising Gynostemma pentaphyllum extract, Coleus forskohlii extract, Zingiber officinale extract and piperine, for increasing metabolic efficiency and inhibition of adipogenesis.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: April 16, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Mitchell Chavez
  • Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
    Patent number: 10258691
    Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: April 16, 2019
    Assignee: Signpath Pharma, Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed, Stephen W. Burgess, Walter A. Shaw
  • Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
    Patent number: 10238602
    Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a phosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug, and one or more organoleptic, thixotropic, or both organoleptic and thixotropic agents.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: March 26, 2019
    Assignee: Signpath Pharma, Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed
  • ALCOHOLIC BEVERAGE COMPOSITION CONTAINING BACILLUS COAGULANS
    Publication number: 20190085277
    Abstract: A probiotic-alcoholic beverage composition comprising Bacillus coagulans is disclosed herein wherein the said spore or vegetative cell of Bacillus coagulans exhibited high recovery, tolerability, compatibility and viability of spores and vegetative cells after brewing. Methods for brewing an alcoholic beverage composition comprising Bacillus coagulans wherein said spore or bacterium is added during pre-fermentation, during fermentation and post fermentation stages are also disclosed.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 21, 2019
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed, Kirankumar Beede
  • PROCESS FOR PREPARING TRIPEPTIDE CONTAINING OLEANOLIC ACID AND ITS THERAPEUTIC APPLICATIONS THEREOF
    Publication number: 20190083378
    Abstract: The present disclosure provides oleanoyl tripeptide to prevent skin aging. More specifically the invention discloses the anti-collagenase, anti-elastase, enhancement of TGF-? secretion in fibroblasts, UV protection, oxidative stress protection, and other properties of the oleanoyl-KVK tripeptide which aids in preventing skin aging.
    Type: Application
    Filed: September 19, 2018
    Publication date: March 21, 2019
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Rajendran Ramanujam
  • ANTI-POLLUTION COMPOSITIONS CONTAINING BACILLUS COAGULANS
    Publication number: 20190060216
    Abstract: Disclosed are the anti-pollution effects of probiotic bacteria Bacillus coagulans MTCC 5856. More specifically the invention discloses the use of probiotic bacteria Bacillus coagulans MTCC 5856 in protecting mammalian skin against the harmful effects of UV and different environmental pollutants. The use of Bacillus coagulans MTCC 5856, as an antioxidant, skin rejuvenating and cleansing agent is also disclosed.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 28, 2019
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Shaheen Majeed
  • COMPOSITIONS COMPRISING BETA-GLUCOGALLIN AND THERAPEUTIC APPLICATIONS THEREOF IN CONTROLLED KINETICS OF CARBOHYDRATE BREAKDOWN AND MONOSACCHARIDE ABSORPTION
    Publication number: 20190060337
    Abstract: Disclosed are the compositions for the effective regulation of carbohydrate breakdown and absorption. More specifically, the invention discloses compositions containing at least 10% w/w or above of 1-O-galloyl-?-D-glucose (?-glucogallin) and additionally comprising of about 10% w/w to greater than 60% w/w total mucic acid gallates for the effective regulation of carbohydrate breakdown and absorption by the inhibition of enzymes amylase, glucosidase and dipeptidyl peptidase.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 28, 2019
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • Composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof
    Patent number: 10172903
    Abstract: Disclosed are methods of managing hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: January 8, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Douglas Kalman, Beena Bhat, Priti Vaidyanathan, Sarang Bani, Anjali Pandey, Suresh Karri
  • Bacillus coagulans MTCC 5856 for the management of major depressive disorder
    Patent number: 10166261
    Abstract: The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (MDD). Specifically, the invention discloses the method of therapeutically managing MDD in mammals with Irritable bowel syndrome using probiotic strain Bacillus coagulans MTCC 5856.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 1, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali
  • PROCESS FOR THE PREPARATION OF STANDARDIZED COMPOSITION OF ARJUNOGLUCOSIDE FROM THE BARK OF Terminalia arjuna
    Publication number: 20180370885
    Abstract: Disclosed is a novel process for the isolation of bioactive compounds from Terminalia arjuna. More specifically, the invention discloses a process for isolation and enrichment of bioactive compounds Arjunic acid, Arjunolic acid, Arjungenin, Arjunetin, Arjunoglucoside-I, Arjunoglucoside-II, and Catechin from the bark of Terminalia arjuna. The invention also discloses a composition standardized to contain 3% arjunoglucosides isolated from the bark of Terminalia arjuna.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Beena Bhat
  • GARCINOL COMPOSITIONS FOR THERAPEUTIC MANAGEMENT OF ENDOPLASMIC RETICULUM STRESS
    Publication number: 20180369166
    Abstract: Disclosed is the use of garcinol for the therapeutic management of ER stress. More specifically, the invention discloses the ability of garcinol in decreasing ER stress and mitigating toxicity by reducing protein aggregation and decreasing expression of ER stress markers SXBP, GRP78 and ATF4, which indicates translational attenuation and recovery in hyperglycemia, paracetamol, alcohol, thapsigargin and high fat diet induced toxicity models.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 27, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • COMPOSITIONS AND METHODS FOR BETA SECRETASE INHIBITION
    Publication number: 20180360800
    Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 20, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • NEUROPROTECTIVE COMPOSITIONS AND THEIR USE
    Publication number: 20180360801
    Abstract: Disclosed are compositions containing not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of memory impairment and cognitive dysfunction. More specifically, the invention discloses the use of abovementioned compositions for the management of cognitive impairment induced by chemotherapy and hyperglycemia.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • ANTI-OBESITY POTENTIAL OF GARCINOL
    Publication number: 20180360776
    Abstract: Disclosed are compositions containing garcinol for the therapeutic management of obesity. More specifically, the invention relates to the use of garcinol for a) maintaining energy balance in mammalian adipose cellular systems b) management of hypercholesterolemia and c) reducing weight gain in mammals. The modification of gut microbiota and the increase of beneficial microbe, Akkermansia muciniphila by garcinol are also disclosed.
    Type: Application
    Filed: June 13, 2018
    Publication date: December 20, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • HYPOLIPIDEMIC EFFECTS OF Bacillus coagulans
    Publication number: 20180353553
    Abstract: Disclosed is the hypolipidemic potential of Bacillus coagulans. More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.
    Type: Application
    Filed: February 22, 2018
    Publication date: December 13, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed
  • COMPOSITIONS AND METHODS FOR REDUCING FLATULENCE
    Publication number: 20180353555
    Abstract: Disclosed are the methods and compositions for the reduction of intestinal gas/flatulence. Specifically a method for reducing flatulence using a composition containing probiotic bacteria Bacillus coagulans MTCC 5856 is disclosed. More specifically, the invention discloses a method for inhibiting the growth of microorganisms that facilitate the production of intestinal gas, using a composition containing probiotic bacteria Bacillus coagulans MTCC 5856.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 13, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed
  • COMPOSITION CONTAINING OROXYLIN A AND METHOD OF EXTRACTION THEREOF
    Publication number: 20180344788
    Abstract: Disclosed are the compositions comprising bioactive components Oroxylin A, Baicalein, Chrysin, and their glucuronides Oroxylin A-7-glucuronide, Baicalein-7-glucuronide and Chrysin-7-glucuronide, isolated from the bark of Oroxylum indicum, and the process of isolating the said bioactives.
    Type: Application
    Filed: November 7, 2017
    Publication date: December 6, 2018
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Beena Bhat, Anurag Pande